VYR-203

VYR-203 is a precision imaging diagnostic agent currently in preclinical development by Vyripharm International for the management of epilepsy. Developed within Vyripharm's nuclear medicine and precision medicine framework, the agent is intended to enhance the visualization and localization of epileptic activity in the brain. As a diagnostic tool, it aims to provide clinicians with more accurate data for the diagnosis and treatment planning of seizure disorders, potentially identifying specific biomarkers or metabolic changes associated with epilepsy. The program is part of a broader pipeline at Vyripharm that integrates bioinformatics and medical cannabinoid research with advanced nuclear imaging techniques.